Intus Bio Strengthens Industry Leading Microbiome Platform with Acquisition of Pattern Genomics

Intus Biosciences, LLC (Intus Bio), creators of the industry-leading Titan-1 microbiome research and testing platform has announced the strategic acquisition of Pattern Genomics, a developer of advanced genomic analysis software tools. This transaction was made possible with the support of Connecticut Innovations, an investor in both companies.

Latest Insights: How to Get Started with Prompt Engineering in Generative AI Projects

The development enhances Intus Bio’s portfolio of end-to-end data-driven solutions for microbiome discovery and understanding. The company has a long history of collaboration with Pattern Genomics and a deep appreciation of the technology being acquired.

The Intus Bio Titan-1 platform combines patented assays and next-generation proprietary analysis tools for an unprecedented ability to generate high accuracy, high-resolution strain-level data on a high-throughput basis. The integration of Pattern Genomics’ technology brings additional machine learning tools for biomarker discovery and patient stratification, across extensive datasets and populations.

As part of the transaction, Pattern Genomics Founder and President, Daniel Fasulo has joined Intus Bio as Head of IT and Bioinformatics.

“We’re grateful for the support of Connecticut Innovations, as we add the impressive technology of Pattern Genomics to Intus Bio. Together, we have an unmatched ability to produce and analyze high-resolution bacterial data at scale, creating incredible opportunities across every aspect of healthcare” said Paul Denslow, Intus Bio’s CEO. “We are also very pleased to have Dan join the Intus Bio leadership team, as he’s a fantastic addition we already know well.”

Recommended: AiThority Interview with Brigette McInnis-Day, Chief People Officer at UiPath

“After nearly 11 years of developing a portfolio of bioinformatics technologies at Pattern Genomics, I am thrilled with this transaction and to join the Intus Bio team,” said Daniel Fasulo, President of Pattern Genomics. “There is no better home for Pattern than Intus Bio, as they bring microbiome technologies into practical medical and pharmaceutical applications.”

“Intus Bio has acquired a powerful asset in Pattern, adding to their already impressive and groundbreaking Titan-1 assay and analysis platform,” said Dan Wagner, Senior Managing Director of Investments at Connecticut Innovations. “The exciting combination of these technologies only increases their significant potential to impact the healthcare industry. We look forward to being part of Intus Bio’s future success.”

Latest Interview Insights : AiThority Interview with Abhay Parasnis, Founder and CEO at Typeface

[To share your insights with us, please write to sghosh@martechseries.com]